Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Recombinant human mannan-binding lectin

A mannan, combined technology, applied in the field of preparing MBL-containing compositions, can solve problems such as lack of ability

Inactive Publication Date: 2006-01-04
斯蒂芬·蒂尔 +2
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the capabilities of currently known in vitro synthetic systems for producing this rMBL have proven to be significantly deficient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant human mannan-binding lectin
  • Recombinant human mannan-binding lectin
  • Recombinant human mannan-binding lectin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0059] The immune system has a relatively strong ability to prevent infection, which is decisively important for the homeostasis and thus for the survival or maintenance of life. It is therefore of considerable importance to identify compounds that play a role in these processes. Intensive studies of this decade have revealed that mannan-binding lectins (MBLs) are very diverse macromolecules, which are thought to be active, for example, in the innate immune system.

[0060] As described above, it is possible according to the present invention to prepare a human recombinant mannan-binding lectin (MBL) composition having a size distribution profile 50% identical to natural human MBL.

[0061] MBL compositions were prepared according to the methods described above and subjected to affinity chromatography in order to separate other oligomers from higher order MBL oligomers.

[0062] Culture broths containing various MBL oligomers were subjected to affinity chromatography on carbo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to treatment on immune system diseases which includes the treatment on the defect in the immune system. The invention includes the preparation of a novel expressing construction body for coding the MBL of human, a novel preparation of recomposing the MBL of human with a high similarity to a natural MBL of human and also includes the application of the compound in combinations, drugs and treatment on the state correlative with an immune restraining state and / or the MBL defect state (including a latent state). An MBL defect state is correlative with the susceptibility increase of infection. More concretely, the invention relates to the treatment on the state (including the latent state, namely the state needs not to be treated currently). The treatment aims at human beings and animals the immune systems of which are similar to human beings.

Description

[0001] This application is a divisional application of Chinese patent application 00809713.5 with an international filing date of May 10, 2000, and the title of the invention is "recombinant human mannan-binding lectin". [0002] The present invention relates to methods of preparing MBL-containing compositions, and to the treatment of diseases and disorders of the immune system, including the treatment of internal deficiencies in the immune defense system. More specifically, the present invention relates to the treatment of mannan-binding lectin (MBL) deficiency or its latent state associated with increased susceptibility to infection. The present invention further relates to the preparation of a new expression construct encoding human MBL, a new recombinant preparation of human MBL, and also includes conditions related to immunosuppressive chemotherapy and / or MBL deficiency states (including latent states, i.e. non- The compound is used in the treatment method of diseases such ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/47C12N15/12C12N5/06A61K38/17A61P35/00A61P31/18
Inventor 斯蒂芬·蒂尔詹斯·C·詹斯尼厄斯托马斯·V·詹森
Owner 斯蒂芬·蒂尔
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com